{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:06:42Z","timestamp":1787540802788,"version":"build-2736575974"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ck0106837"],"award-info":[{"award-number":["JP25ck0106837"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Local therapy is not considered a standard treatment option for patients with high-volume metastatic prostate cancer. Our research group\u2019s previous retrospective study indicated potential benefits of local radiotherapy (LRT) for some high-volume metastatic prostate cancer patients, but prospective studies have yet to confirm these findings. We have thus planned a multicenter, open-label, randomized controlled phase III trial to confirm the efficacy of adding LRT to systemic hormonal therapy with androgen deprivation therapy plus an androgen receptor pathway inhibitor in a population of high-volume metastatic prostate cancer patients for whom the hormonal therapy is effective for 6\u00a0months. The primary endpoint is failure-free survival, defined as the time from randomization to prostate-specific antigen progression, radiological progression, clinical progression, or death from any cause. We aim to enroll 360 patients from 56 institutions over a 4-year period. This trial is registered at the Japan Registry of Clinical Trials (study no. jRCT1031220676).<\/jats:p>","DOI":"10.1093\/jjco\/hyaf157","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:59:27Z","timestamp":1758887967000},"page":"104-109","source":"Crossref","is-referenced-by-count":3,"title":["Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study)"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1082-6089","authenticated-orcid":false,"given":"Naoki","family":"Terada","sequence":"first","affiliation":[{"name":"Department of Urology, University of Fukui , Eiheiji ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-1860","authenticated-orcid":false,"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-9631","authenticated-orcid":false,"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Urology, Aichi Cancer Center , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine , Tsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-782X","authenticated-orcid":false,"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Kagawa University , Takamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sekino","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5100-3863","authenticated-orcid":false,"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Tsukuba Hospital , Tsukuba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Toyama , Toyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-8746","authenticated-orcid":false,"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Urological Oncology Study Group (UOSG) and the Radiation Therapy Study Group (RTSG) of the Japan Clinical Oncology Group (JCOG) Kamoto Toshiyuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2026012223581156600_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026012223581156600_ref2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10147-024-02575-3","article-title":"Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan","volume":"29","author":"Sasaki","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026012223581156600_ref3","article-title":"NCCN Guidelines Prostate Cancer V.1.2023"},{"key":"2026012223581156600_ref4","author":"EAU Guideline","year":"2020"},{"key":"2026012223581156600_ref5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"key":"2026012223581156600_ref6","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"2026012223581156600_ref7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jjco\/hyac035","article-title":"Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer","volume":"52","author":"Terada","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2026012223581156600_ref8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/bco2.35","article-title":"Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer","volume":"1","author":"Terada","year":"2020","journal-title":"BJUI Compass"},{"key":"2026012223581156600_ref9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026012223581156600_ref10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026012223581156600_ref11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"},{"key":"2026012223581156600_ref12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2307\/2531701","article-title":"Changing frequency of interim analysis in sequential monitoring","volume":"45","author":"Lan","year":"1989","journal-title":"Biometrics"},{"key":"2026012223581156600_ref13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0197-2456(82)90022-8","article-title":"An aid to data monitoring in long-term clinical trials","volume":"3","author":"Halperin","year":"1982","journal-title":"Control Clin Trials"},{"key":"2026012223581156600_ref14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/sim.4780121516","article-title":"Applying Bayesian ideas in drug development and clinical trials","volume":"12","author":"Spiegelhalter","year":"1993","journal-title":"Stat Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/104\/64521684\/hyaf157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/104\/64521684\/hyaf157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:58:17Z","timestamp":1769144297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/1\/104\/8276080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf157","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,6]]}}}